Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Manitoba

$27,000.00

Prenatal decision-making for life-threatening hypophosphatasia (HPP) in the era of enzyme replacement therapy.

FY 2025-26

Summary
Hypophosphatasia, or HPP, is a genetic condition caused by a change (also called a variant) in the ALPL gene. Variants in this gene result in decreased activity of an enzyme called alkaline phosphatase, which is crucial for bone and tooth formation during pregnancy. A diagnosis of a life-threatening form of HPP has historically led to a very high infant death rate in the first year of life. Life-threatening HPP can be detected by prenatal ultrasound and DNA testing, and a recently approved enzyme-replacement therapy (ERT) can begin after birth. Although ERT has significantly reduced the death rate, surviving children still face significant challenges with growth and development, loss of primary teeth, seizures, and physical disability. An exciting new treatment option called in-utero enzyme-replacement therapy (IU-ERT) is being considered for HPP. IU-ERT involves injecting the treatment directly into a baby’s circulation system before birth, guided by ultrasound. IU-ERT for HPP is currently being explored in an early phase clinical trial with the aim of improving bone formation, survival, and quality of life for these children. The aim of this research study is to understand the perceived benefits, barriers, and attitudes of IU-ERT among families with prior experience with life-threatening HPP, or couples who are at risk of having a child with life-threatening HPP. Interviews with these families will explore their experiences, and the findings of this study will directly inform appropriate and meaningful genetic counselling for this patient population.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572990
Name
Shah Shreya
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Prenatal decision-making for life-threatening hypophosphatasia (HPP) in the era of enzyme replacement therapy.
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Genetic Condition; Genetic Counselling; In-Utero Enzyme Replacement Therapy; Life-Threatening Hypophosphatasia; Patient Perspectives; Qualitative Research; Rare Inherited Condition
Abstract
Hypophosphatasia, or HPP, is a genetic condition caused by a change (also called a variant) in the ALPL gene. Variants in this gene result in decreased activity of an enzyme called alkaline phosphatase, which is crucial for bone and tooth formation during pregnancy. A diagnosis of a life-threatening form of HPP has historically led to a very high infant death rate in the first year of life. Life-threatening HPP can be detected by prenatal ultrasound and DNA testing, and a recently approved enzyme-replacement therapy (ERT) can begin after birth. Although ERT has significantly reduced the death rate, surviving children still face significant challenges with growth and development, loss of primary teeth, seizures, and physical disability. An exciting new treatment option called in-utero enzyme-replacement therapy (IU-ERT) is being considered for HPP. IU-ERT involves injecting the treatment directly into a baby’s circulation system before birth, guided by ultrasound. IU-ERT for HPP is currently being explored in an early phase clinical trial with the aim of improving bone formation, survival, and quality of life for these children. The aim of this research study is to understand the perceived benefits, barriers, and attitudes of IU-ERT among families with prior experience with life-threatening HPP, or couples who are at risk of having a child with life-threatening HPP. Interviews with these families will explore their experiences, and the findings of this study will directly inform appropriate and meaningful genetic counselling for this patient population.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shah, Shreya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~